DGAP-News: EVOTEC AND SANOFI IN EXCLUSIVE TALKS TO CREATE AN EVOTEC-LED INFECTIOUS DISEASE OPEN INNOVATION R&D PLATFORM
08.03.2018 (www.4investors.de) -
DGAP-News: Evotec AG / Key word(s): Miscellaneous
EVOTEC AND SANOFI IN EXCLUSIVE TALKS TO CREATE AN EVOTEC-LED INFECTIOUS DISEASE OPEN INNOVATION R&D PLATFORM
08.03.2018 / 07:43
The issuer is solely responsible for the content of this announcement.
Evotec-led platform open to academia, biotechnology and pharmaceutical companies, foundations, and government agencies
Evotec-Led platform expands current initiatives to accelerate research and development ("R&D") of novel anti-infectives
Sanofi to licence more than 10 infectious disease ("ID") R&D assets to Evotec while retaining option rights for development and commercialisation
Transaction excludes Sanofi's vaccine R&D unit and related projects
Sanofi to transfer approximately 100 employees to Evotec
Sanofi to provide support to Evotec including a one-time, upfront payment of EUR 60 m to support success of Infectious Disease assets
Transaction is expected to close in the first half of 2018
Hamburg, Germany; Paris, France, 08 March 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France.
In support of this platform, Sanofi will licence most of its infectious disease research and early-stage development portfolio and transfer its infectious disease research unit to Evotec. The transaction excludes the vaccine R&D unit and related projects. Evotec will combine its drug discovery and development expertise with these new assets and experts, committing to the expansion and acceleration of anti-infective drug discovery and development through open collaborations with other pharmaceutical and biotechnology companies, foundations, academia, and government agencies. More than 150 scientists within Evotec will be active in this field.
Sanofi will pay Evotec an initial one-time cash upfront payment of EUR 60 m and provide significant further long-term funding to ensure support and progression of the portfolio. Sanofi will retain certain option rights on the development, manufacturing, and commercialisation of anti-infective products and will continue to be involved in infectious disease through its vaccines research and development and its global health programs.
Under the agreement, Evotec will integrate Sanofi's infectious disease research unit, which includes more than 100 employees into its global drug discovery and development operations. The transferred positions will be associated with specific commitments of employment for 5 years and will continue to be based near Lyon, taking advantage of the location's scientific and medical ecosystems.
Evotec will expand its existing long-term initiatives focused on innovation to fight infectious diseases including the maintenance of a portfolio of projects aimed at diseases affecting the developing world. The focus of drug discovery will at the outset be on new mode-of-action antimicrobials.Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: "Since the acquisition of Euprotec (UK) in 2014, Evotec has had a significant strategic interest and demonstrated expertise in infectious diseases research, with an ambition to grow and become the drug discovery and development leader in this space together with its partners. We are pleased to be working and expanding our strategic relationship with Sanofi, which has a long history in providing novel anti-infective agents to markets globally. Finding a way to motivate more public funding and academic initiatives for the progress of novel anti-infectives on Evotec's platform will be a key success factor for this initiative."
"Sanofi has a long and established history in the fight against infectious diseases, and we remain committed to addressing global health challenges through our development efforts and vaccines", says Dr Elias Zerhouni, President Global R&D for Sanofi. "Research in the field of anti-infectives is an area where building critical mass through partnering is particularly important. This new French-based open innovation center will benefit from the high quality science ecosystem. Evotec is a trusted partner in drug discovery and has the ambition and capacity to become a real leader in the fight against infectious diseases."
This transaction is expected to close in the first half of 2018, subject to finalisation of definitive agreements and completion of the appropriate social process. This project will be conducted in full respect of social dialogue with employee's representatives.
ABOUT INFECTIOUS DISEASES
Infectious diseases are caused by bacteria, viruses, fungi or parasites and can be spread, directly or indirectly, from one person to another. Treatments for infectious diseases include antibiotics and anti-viral medications. Today, infectious diseases propagated by bacteria are becoming increasingly resistant to many antibiotics and any use of antibiotics reduces the effectiveness of these drugs for other patients. The World Health Organization ("WHO") has deemed antibiotic resistance to be one of the three greatest threats to human health today. Almost a million people die of resistant infections a year. It is also estimated that by 2050, 10 million lives a year and a cumulative 100 trillion dollars of economic output are at risk due to the rise of drug resistant infections if solutions to this problem are not identified now. Thus, there is a critical need to research and develop medical solutions to combat antibiotic resistant bacteria.
Evotec invites you to join a conference call to provide information regarding this major alliance with Sanofi. The conference will be held in English.Conference call details
Date: Thursday, 08 March 2018
Time: 2.00 pm CET (1.00 pm GMT, 8.00 am EST)
From France +33 170750705
From Germany: +49 (69) 22 22 29 043
From Italy: +39 0236013806
From UK: +44 2030092452
From USA: +1 8554027766
Access Code: 37969784#
A simultaneous slide presentation for participants dialling in via phone is available at http://www.audio-webcast.com/ password: evotec080318.
To join the audio webcast and to access the presentation slides you will find a link on our home page www.evotec.com shortly before the event.
A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialling +49 69 22 22 33 985 (Germany) and+33 170 750 767 (France), +44 20 3426 2807 (UK) and in the US by dialling +1 866 535 8030. The access code is 654573#. The on-demand version of the webcast will be available on our website: https://www.evotec.com/article/en/Investors/Financial-Reports-2015-2017/188/6ABOUT SANOFISanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life
Media Relations Contact
Tel.: +33 (0)1 53 77 46 46
ABOUT EVOTEC AGEvotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.FORWARD LOOKING STATEMENTSInformation set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, firstname.lastname@example.org
08.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Manfred Eigen Campus / Essener Bogen 7
+49 (0)40 560 81-0
+49 (0)40 560 81-222
Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
End of News
DGAP News Service
Francotyp-Postalia hat das Tor zum Internet der Dinge
IPO-Kandidat Homes + Holiday: „Unser Geschäftsmodell hat sich bewährt und ist skalierbar“
Staramba: „Wir haben unsere Lehren gezogen“